Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks

Jakob German,Mattia Cordioli,Sarah Urbut,Veronica Tozzo,Kadri Arumae,Roelof A.J. Smit,Jiwoo Lee,Josephine Li,Adrian Janucik,Yi Ding,Akintunde Akinkuolie,Henrike Heyne,Andrea Eoli,Chadi Saad,Yasser Al-Sarraj,Rania Abdel-latif,Alexandra Barry,Zhe Wang,Estonian Biobank research team,Pradeep Natarajan,Samuli Ripatti,Anthony Philippakis,Bogdan Pasaniuc,Lukasz Szczerbinski,Adam Kretowski,Hamdi Mbarek,Ruth J.F. Loos,Uku Vainik,Andrea Ganna

DOI: https://doi.org/10.1101/2024.09.11.24313458

2024-09-12

Abstract:Obesity is a significant public health concern. GLP-1 receptor agonists (GLP1-RA), predominantly in use as a type 2 diabetes treatment, are a promising pharmacological approach for weight loss, while bariatric surgery (BS) remains a durable, but invasive, intervention. Despite observed heterogeneity in weight loss effects, the genetic effects on weight loss from GLP1-RA and BS have not been extensively explored in large sample sizes, and most studies have focused on differences in race and ethnicity, rather than genetic ancestry. We studied whether genetic factors, previously shown to affect body weight, impact weight loss due to GLP1-RA therapy or BS in 10,960 individuals from 9 multi-ancestry biobank studies in 6 countries. The average weight change between 6 and 12 months from therapy initiation was -3.93% for GLP1-RA users, with marginal differences across genetic ancestries. For BS patients the weight change between 6 and 48 months from the operation was -21.17%. There were no significant associations between weight loss due to GLP1-RA and polygenic scores for BMI or type 2 diabetes or specific missense variants in the GLP1R, PCSK1 and APOE genes, after multiple-testing correction. However, a higher polygenic score for BMI was significantly linked to lower weight loss after BS (+0.7% for 1 standard deviation change in the polygenic score, P = 1.24x10-4). In contrast, higher weight at baseline was associated with greater weight loss. Our findings suggest that existing polygenic scores related to weight and type 2 diabetes and missense variants in the drug target gene do not have a large impact on GLP1-RA effectiveness. Our results also confirm the effectiveness of these treatments across all major continental ancestry groups considered.